[Possibilities, failures and prospects of studies on tumor markers in oncological clinics. 1. (lecture)].
Kushlinskiĭ
N E
NE
D015295:Antigens, Tumor-Associated, Carbohydrate / Q000032:analysis; D014408:Biomarkers, Tumor / Q000145:classification; D018394:CA-125 Antigen / Q000032:analysis; D018395:CA-19-9 Antigen / Q000032:analysis; D002272:Carcinoembryonic Antigen / Q000032:analysis; D003110:Colonic Neoplasms / Q000175:diagnosis; D006801:Humans; D008113:Liver Neoplasms / Q000175:diagnosis; D008991:Monitoring, Physiologic; D018396:Mucin-1 / Q000032:analysis; D009369:Neoplasms / Q000175:diagnosis* / Q000628:therapy; D011379:Prognosis; D012680:Sensitivity and Specificity; D012907:Smoking / Q000009:adverse effects; D013274:Stomach Neoplasms / Q000175:diagnosis; D019396:Tissue Polypeptide Antigen / Q000032:analysis; D000509:alpha-Fetoproteins / Q000032:analysis
D015295:Antigens, Tumor-Associated, Carbohydrate; D014408:Biomarkers, Tumor; C081241:CA 195 antigen; D018394:CA-125 Antigen; D018395:CA-19-9 Antigen; C082699:CA-50 antigen; C083825:CA-72-4 antigen; D002272:Carcinoembryonic Antigen; D018396:Mucin-1; D019396:Tissue Polypeptide Antigen; D000509:alpha-Fetoproteins